New frontiers in cancer research

Date: Tuesday, December 19, 2017
(L-R) Prof. Avigdor Scherz, incumbent of the Yadelle and Robert N. Sklare Professorial Chair in Biochemistry, Department of Plant and Environmental Sciences, Weizmann Institute; and Jonathan A. Coleman, MD, Associate Professor and Urologic Surgeon, Memorial Sloan Kettering Cancer Center. (Credit: Richard DeWitt)

(L-R) Prof. Avigdor Scherz, incumbent of the Yadelle and Robert N. Sklare Professorial Chair in Biochemistry, Department of Plant and Environmental Sciences, Weizmann Institute; and Jonathan A. Coleman, MD, Associate Professor and Urologic Surgeon, Memorial Sloan Kettering Cancer Center. (Credit: Richard DeWitt)

On October 26, nearly 100 guests gathered at the Mortimer B. Zuckerman Research Center in New York to learn about the collaboration between two world-class institutions: the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center (MSK). The event featured the Weizmann Institute’s Prof. Avigdor Scherz and MSK surgeon-scientist Dr. Jonathan Coleman. Prof. Scherz and his longtime Weizmann collaborator, the late Prof. Yoram Salomon, invented a revolutionary, noninvasive approach to fight early-stage prostate cancer. It has now been approved for this use in South America, Europe, and Israel. In the U.S., Prof. Scherz and Dr. Coleman are conducting clinical trials for additional cancers including esophageal, bladder, breast, advanced prostate, and more recently, pancreatic. Guests were inspired to hear about this promising treatment, which holds hope for so many.